Cerus Co. (NASDAQ:CERS) Holdings Raised by Rhumbline Advisers

Rhumbline Advisers lifted its stake in shares of Cerus Co. (NASDAQ:CERS) by 4.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 252,444 shares of the biotechnology company’s stock after purchasing an additional 10,739 shares during the quarter. Rhumbline Advisers owned about 0.14% of Cerus worth $444,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its stake in shares of Cerus by 4.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 192,873 shares of the biotechnology company’s stock valued at $365,000 after purchasing an additional 8,982 shares in the last quarter. Neuberger Berman Group LLC bought a new stake in Cerus in the fourth quarter worth about $26,000. Russell Investments Group Ltd. raised its position in Cerus by 451.1% in the first quarter. Russell Investments Group Ltd. now owns 14,879 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 12,179 shares in the last quarter. Bouvel Investment Partners LLC raised its position in Cerus by 4.7% in the first quarter. Bouvel Investment Partners LLC now owns 269,849 shares of the biotechnology company’s stock worth $510,000 after acquiring an additional 12,224 shares in the last quarter. Finally, Secure Asset Management LLC bought a new stake in Cerus in the second quarter worth about $27,000. 78.37% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Cerus news, CFO Kevin Dennis Green sold 28,385 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total transaction of $61,879.30. Following the sale, the chief financial officer now owns 590,365 shares in the company, valued at approximately $1,286,995.70. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, insider Richard J. Benjamin sold 21,605 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $2.50, for a total value of $54,012.50. Following the transaction, the insider now owns 438,007 shares in the company, valued at approximately $1,095,017.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin Dennis Green sold 28,385 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the transaction, the chief financial officer now owns 590,365 shares in the company, valued at approximately $1,286,995.70. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company’s stock.

Cerus Price Performance

Shares of Cerus stock opened at $1.78 on Friday. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 1.29. The company’s 50-day moving average price is $2.14 and its two-hundred day moving average price is $1.94. Cerus Co. has a 52 week low of $1.21 and a 52 week high of $2.59. The stock has a market cap of $329.10 million, a PE ratio of -10.47 and a beta of 1.19.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. The firm had revenue of $45.08 million for the quarter, compared to analysts’ expectations of $42.50 million. Cerus had a negative net margin of 14.15% and a negative return on equity of 44.27%. During the same period in the previous year, the business earned ($0.07) earnings per share. As a group, sell-side analysts anticipate that Cerus Co. will post -0.13 EPS for the current fiscal year.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.